secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2026-05-18T12:56:23+00:00
Accession:  0001493152-26-024095
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M
----------------------------------------------------------------------------

- Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.
- Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.
- Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.
- Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.
- UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/0001493152-26-024095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226024095/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-024095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer